The rapid emergence of antimicrobial resistance (AMR) poses a critical threat to global health, demanding innovative research strategies beyond conventional ...
Canadians swallow millions of pills every day to treat common health issues like high blood pressure, high cholesterol and ...
Monthly olezarsen reduced triglycerides and apolipoprotein B in patients with hypertriglyceridemia but may have no impact on ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs ...
The firm aims to develop siRNAs and antisense oligonucleotides for common diseases that require targeting tissues beyond the liver.
RNA therapies present significant opportunities in targeting a broad range of diseases through various innovative approaches, including antisense oligonucleotides, siRNAs, mRNA vaccines, and aptamers.
Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways ...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...
Alloy Therapeutics inks multi-target collaboration and license pact with Biogen for use of Alloy’s AntiClastic ASO platform: Boston, Massachusetts Wednesday, April 8, 2026, 16:0 ...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...
Columbia's Silence ALS program is testing spinal antisense therapy in a high‑risk patient; early EMG tests normalized.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results